Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001863769-25-000010
Filing Date
2025-09-30
Accepted
2025-09-30 17:01:06
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 33770
2 TRANSACTIONS RELATING TO THE ORDINARY SHARES OF THE ISSUER DURING THE PAST SIXTY ex-10-09302025_090906.htm EX-10.2 3519
3 JOINT FILING AGREEMENT ex-99-09302025_090907.htm EX-99.1 11036
  Complete submission text file 0001863769-25-000010.txt   50080
Mailing Address 11711 N. MERIDIAN STREET SUITE 300 CARMEL IN 46032
Business Address 11711 N. MERIDIAN STREET SUITE 300 CARMEL IN 46032 3179893100
MBX Biosciences, Inc. (Subject) CIK: 0001776111 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-94623 | Film No.: 251361320
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 1001 PAGE MILL ROAD BUILDING 4, SUITE B PALO ALTO CA 94304
Business Address 1001 PAGE MILL ROAD BUILDING 4, SUITE B PALO ALTO CA 94304 650-325-5156
Frazier Life Sciences Public Fund, L.P. (Filed by) CIK: 0001863769 (see all company filings)

EIN.: 862999645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A